Stock Track | INNOGEN-B Plummets 5.46% Intraday as Lock-Up Period Expires and Financial Losses Widen

Stock Track05-14

INNOGEN-B's stock price plummeted 5.46% during intraday trading on Thursday, continuing a downward trend following a significant surge earlier in the week.

The decline comes ahead of the expiration of the lock-up period for the company's cornerstone investors. According to company announcements, the lock-up period ended today, with the related shares becoming freely tradable tomorrow. The cornerstone investors collectively hold 4.201 million shares, creating potential selling pressure as these shares become available on the market.

Additionally, the company reported weak financial results for the 2025 fiscal year, with revenue of RMB 132 million primarily from its product ESUPAGLUTIDE α sales in China, but recorded a net loss of RMB 341 million, representing a year-on-year expansion of 95.41%. Research and development expenses for the period doubled to RMB 206 million, further contributing to investor concerns about the company's financial health.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147698784?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 14:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147698784","market":"sg","top_or_hot":-1,"title":"Stock Track | INNOGEN-B Plummets 5.46% Intraday as Lock-Up Period Expires and Financial Losses Widen","media":"Stock Track","content":"<p>INNOGEN-B's stock price plummeted 5.46% during intraday trading on Thursday, continuing a downward trend following a significant surge earlier in the week.</p><p>The decline comes ahead of the expiration of the lock-up period for the company's cornerstone investors. According to company announcements, the lock-up period ended today, with the related shares becoming freely tradable tomorrow. The cornerstone investors collectively hold 4.201 million shares, creating potential selling pressure as these shares become available on the market.</p><p>Additionally, the company reported weak financial results for the 2025 fiscal year, with revenue of RMB 132 million primarily from its product ESUPAGLUTIDE α sales in China, but recorded a net loss of RMB 341 million, representing a year-on-year expansion of 95.41%. Research and development expenses for the period doubled to RMB 206 million, further contributing to investor concerns about the company's financial health.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | INNOGEN-B Plummets 5.46% Intraday as Lock-Up Period Expires and Financial Losses Widen</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | INNOGEN-B Plummets 5.46% Intraday as Lock-Up Period Expires and Financial Losses Widen\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-14 14:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOGEN-B's stock price plummeted 5.46% during intraday trading on Thursday, continuing a downward trend following a significant surge earlier in the week.</p><p>The decline comes ahead of the expiration of the lock-up period for the company's cornerstone investors. According to company announcements, the lock-up period ended today, with the related shares becoming freely tradable tomorrow. The cornerstone investors collectively hold 4.201 million shares, creating potential selling pressure as these shares become available on the market.</p><p>Additionally, the company reported weak financial results for the 2025 fiscal year, with revenue of RMB 132 million primarily from its product ESUPAGLUTIDE α sales in China, but recorded a net loss of RMB 341 million, representing a year-on-year expansion of 95.41%. Research and development expenses for the period doubled to RMB 206 million, further contributing to investor concerns about the company's financial health.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02591","symbol_name":"银诺医药-B","start_time":0,"source_url":"","article_id":"1147698784","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147698784","pubTimestamp":1778739592,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"INNOGEN-B's stock price plummeted 5.46% during intraday trading on Thursday, continuing a downward trend following a significant surge earlier in the week.The decline comes ahead of the expiration of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02591":"银诺医药-B"},"translate_title":"个股追踪|英诺健-B盘中暴跌5.46%锁定期到期财务亏损扩大","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"INNOGEN-B's stock price plummeted 5.46% during intraday trading on Thursday, continuing a downward trend following a significant surge earlier in the week.The decline comes ahead of the expiration of the lock-up period for the company's cornerstone investors. According to company announcements, the lock-up period ended today, with the related shares becoming freely tradable tomorrow. The cornerstone investors collectively hold 4.201 million shares, creating potential selling pressure as these shares become available on the market.Additionally, the company reported weak financial results for the 2025 fiscal year, with revenue of RMB 132 million primarily from its product ESUPAGLUTIDE α sales in China, but recorded a net loss of RMB 341 million, representing a year-on-year expansion of 95.41%. Research and development expenses for the period doubled to RMB 206 million, further contributing to investor concerns about the company's financial health.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147698784","isCrawlerRequest":true}